Global Exosomes Market

Global Exosomes Market Size, Share, Growth Analysis, By Application(Diagnostic, therapeutic applications), By Product(Instruments, reagents), By End-User(Cancer institute, hospitals), By Workflow(Isolation, Downstream Analysis), By Biomolecule Type(Non-coding RNA, mRNA) - Industry Forecast 2024-2031


Report ID: SQMIG35H2198 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 145 | Figures: 78

Global Exosomes Market Insights

Exosomes Market size was valued at USD 84.49 billion in 2019 and is poised to grow from USD 112.25 billion in 2023 to USD 8793.95 billion by 2031, growing at a CAGR of 32.75% in the forecast period (2024-2031).

Extracellular vesicles (EVs), another name for exosomes, are encapsulated within a single outer membrane. They are released by all cell types and can be found in bile, lymph, serum, stomach acid, synovial fluid, tears, plasma, semen, breast milk, CSF, amniotic fluid, and bronchial fluid. These vesicles serve as pathways for cell communication as they transport proteins and genetic material throughout the body. Technology breakthroughs in exosome separation and analytical techniques, sophisticated exosome applications, expansion of government and non-government initiatives for exosome research, and the rising incidence of cancer are the main reasons propelling the sector.

Despite the negative effects in 2019, the pandemic has created a number of new opportunities for the creation of COVID-19 vaccines and therapies using exosomes, which is anticipated to spur industrial growth in the years to come. For instance, in August 2022, scientists at North Carolina State University created an exosome-based inhalable COVID-19 vaccine. Exosomes can also be used to track the development of a variety of illnesses, including cancer, infectious diseases, neurological illnesses, and cardiovascular diseases (CVDs).

Exosomes' benefits in drug delivery, including their permeability of biological barriers, minimal immunogenicity and toxicity, and stability in circulation, are also expanding the therapeutic uses in this field. Therefore, it is anticipated that the industry would be driven over the projection period by the prospective uses of extracellular vesicles in diagnostics, treatments, and vaccine development. A great demand for efficient new therapeutic alternatives for the detection and treatment of the disease is being created by the rising incidence of cancer. For instance, the World Health Organization (WHO) estimates that approximately 10 million people will die from cancer in 2019, making it one of the leading causes of death globally.

Additionally, the American Cancer Society estimates that by the end of 2022, there would have been 609,360 cancer deaths and 1,918,030 new cancer cases in the United States. Additionally, it is projected that during the projection years, technological developments in exosome isolation and analytical methods would accelerate market growth.

US Exosomes Market is poised to grow at a sustainable CAGR for the next forecast year.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

US Exosomes Market is poised to grow at a sustainable CAGR for the next forecast year.

The Global Exosomes market is relatively fragmented, with a high level of competition. Companies are working on new product launches and other initiatives to provide better equipment to their customers and expand their companies globally. These industry leaders are expanding their client base in a variety of ways, and many organizations are forming strategic and creative partnerships with other start-up businesses in order to increase market share and profitability. 'Thermo Fisher Scientific Inc.', 'QIAGEN N.V.', 'NanoSomiX Inc.', 'System Biosciences LLC', 'Malvern Instruments Ltd.', 'Bio-Techne Corporation', 'Norgen Biotek Corp.', 'Lonza Group Ltd.', 'HansaBioMed Life Sciences Ltd.', 'AMS Biotechnology (Europe) Ltd.', 'Hitachi Chemical Co. Ltd.', 'Evomic Science LLC', 'Codiak Biosciences Inc.', 'Exosome Diagnostics Inc.', 'Aethlon Medical Inc.', 'Evox Therapeutics Ltd.', 'Jazz Pharmaceuticals plc', 'ReNeuron Group plc', 'Capricor Therapeutics Inc.', 'Stem Cells Inc.'

Most pharmaceutical, biopharmaceutical, and medical device businesses make significant investments in the creation of new medications and equipment. The pharmaceutical sector invests much in R&D. Pharmaceutical businesses spend in R&D to provide the market with cutting-edge, high-quality goods. According to trends, the leading pharmaceutical firms are enhancing their R&D productivity by significant long-term expenditures in R&D as well as through joint R&D projects.

Exosomes can be used as a treatment platform for a variety of illnesses, including COVID-19. Exosomes are used in medicine to deliver therapeutic cargo components while avoiding immune rejection and cellular toxicity. They are cell-free options for treating a variety of illnesses and for tissue regeneration. Exosomal therapy for respiratory viral infections, including SARS-CoV-2, can be created because stem cell-derived exosomes are favorable in utilizing the anti-inflammatory and regenerative characteristics of parent cells.

The North American region holds the largest share of the market. The enhanced healthcare infrastructure, efficient government policies, presence of key players, and greater knowledge of diagnostics and healthcare among the populace are all factors that have contributed to the market expansion in this area. Due to a large number of government-funded research studies on the effects of exosome-based drugs on a variety of cancers, including melanoma, breast cancer, lung cancer, and pancreatic cancer, among others, and key players' collaboration with state universities in the area to conduct clinical trials in the United States, the species is likely to remain the most dominant country during the forecast period.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Exosomes Market

Product ID: SQMIG35H2198

$5,300
BUY NOW GET FREE SAMPLE